Blog - Page 375 of 872

October 7, 2021October 7, 2021

FYidoctors Doubles Retail Offering in Hometown Grande Prairie

FYidoctors announces the addition of its second location in Grande Prairie, Alberta. The newly constructed clinic, which is located on Westgate Drive, marks a significant milestone for the organization, whose entrepreneurial success story began 13 years ago in the growing community. The inaugural location remains its largest clinic in Canada.

“We’re incredibly proud to announce the opening of our second clinic in Grande Prairie, a region long regarded as a foundational part of our history,” said Dr. Alan Ulsifer, CEO and Chairman of FYidoctors. “Our roots are here, and we couldn’t be more thankful to the community that contributed to the success of FYidoctors.”

The new location adds clinic leads Dr. Michael Litchfield and Dr. Joel Heath, both of whom are active members in the Grande Prairie community, having first worked at the FYidoctors location on 99th Street.

“We’re pleased to announce the new addition, which helps meet the growth and vision care needs of Grande Prairie and its surrounding communities,” said Dr. Heath. “As an organization who prides itself in taking a doctor-led, comprehensive approach to vision care, we’re thrilled to add a second location, and to provide new and existing patients with the most current eye care technology available, with the added care and benefits available through FYidoctors,” added Dr. Litchfield.

As part of the grand opening celebrations, on October 1^st, 2021, the FYidoctors Westgate clinic hosted an official ribbon-cutting ceremony alongside the Grande Prairie & District Chamber of Commerce.

Click HERE for the full press release.

CRAVING MIDO: Ready to Restart and to Transform the Wonder into a New Beginning

Starting today, on the MIDO website www.mido.com, visitors to the international eyewear show ‒ buyers, designers, entrepreneurs, opticians, ophthalmologists and eyewear supply chain professionals ‒ can register for the forthcoming edition of the show, set to take place February 12-14, 2022.

The premier global B2B eyewear show is coming back, with in-person participation in complete safety at Fiera Milano Rho, for a not-to-be-missed industry event.
New trends, materials, sustainability, innovation and the future will be the foremost topics of interest.

The 2022 edition will be distinctive and unforgettable: There will be encounters with distinguished guests, awards, honors and previews in the pursuit of “craving a new beginning”. The event will also be complemented by the MIDO 2022 I DIGITAL EDITION, the digital platform launched in June 2021 that helps boost a beneficial connection between the physical and digital worlds.

The craving for renewal and creativity begins with the new 2022 campaign ‒ dynamic, interactive and in real time, complete with augmented reality, employed for the first time by an eyewear trade show ‒ based on the “CRAVING MIDO” claim. It is divided into 4 volumes. Just scan the QR code to view the star players and their stories.

“We crave a restart and we want to do it looking each other in the eyes,” exclaimed President Giovanni Vitaloni. “We want to rebuild, innovate, demonstrate what we are made of – to forge new relationships, strengthen existing ones and get back to making our businesses prosper. First half data on industry performance raised our hopes for the future but we are even more impressed by the robust participation in industry trade shows that are finally popping up in various markets, like DaTE, where the spirit of recovery was in the air,” he concluded.

Click HERE for the full press release.

October 6, 2021October 5, 2021

Bausch + Lomb Announces Statistically Significant Topline Results from Second Phase 3 Trial of NOV03

Bausch + Lomb and Novaliq announced statistically significant topline data from the second Phase 3 (MOJAVE) trial evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). The companies announced statistically significant topline data from the first Phase 3 trial (GOBI trial) in April 2021.

“The findings from this second Phase 3 trial reinforce the results of the first Phase 3 trial and further supports the efficacy and safety profile of NOV03 as a potential important new treatment option for the millions of people living with dry eye disease associated with MGD,” said Joseph C. Papa, chairman and CEO, Bausch Health. “These results mark another important milestone in bringing NOV03 to market as a potential first-in-class treatment, and we anticipate filing a New Drug Application to the U.S. Food and Drug Administration in 2022.”

The MOJAVE trial met both primary sign and symptom endpoints, and also met all of its secondary endpoints, showing statistically significant improvements in each of the signs and symptoms of DED associated with MGD that were evaluated.

“We are extremely pleased by the consistency of the results, which reaffirm the safety and efficacy results for this investigational drug previously demonstrated in a Phase 2 trial and the first Phase 3 trial. This underscores the potential impact NOV03 could have, if approved, in addressing an unmet medical need for the millions of patients with dry eye disease associated with MGD,” said Christian Roesky, Ph.D., CEO, Novaliq.

The clinical development program for NOV03 is expected to conclude with an ongoing multi-center, open-label, single-arm, 12-month safety extension trial (KALAHARI).

Click HERE for the full press release.

Bausch + Lomb Announces Results from First Phase 3 Trial of NOV03

October 6, 2021October 6, 2021

CooperVision: SightGlass Vision Diffusion Optics Technology Demonstrates Significant Reduction in Myopia Progression

CooperVision’s SightGlass Vision Business has revealed two-year clinical study data for its Diffusion Optics Technology^™, which is specifically designed to slow the progression of myopia in children. After two years, children who wore their Diffusion Optics Technology^™-enabled spectacles full time, including not removing them for near vision activities, progressed on average one-half diopter less than those wearing the control spectacles—a reduction of 59%.

The news was presented during a launch event in the Netherlands yesterday, timed with the world’s first commercial launch of the technology. The product will be available from CooperVision to eye care professionals in the Netherlands beginning this month. EssilorLuxottica, which will also introduce the spectacle lenses with Diffusion Optics Technology^™, participated as well.

The CYPRESS clinical study enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada. At the time of enrollment, subjects were 6 to 10 years old having myopia between -0.75 D and -4.50 D.

After two years of wear, 85% of children wearing the innovative spectacle lenses showed less than one diopter of myopia progression. Moreover, the study also showed that 41% of the children wearing spectacle lenses with Diffusion Optics Technology^™ showed no clinically meaningful progression in refractive error after two years versus only 17% in the control group.

Distance visual acuity with lenses incorporating Diffusion Optics Technology^™ was on average better than 6/6 (20/20) at each visit and similar to single vision spectacle lenses at all visits from dispensing through the 24-month visit. In the trial, children on average wore both the test lenses and standard single vision spectacle lenses more than 12 hours each day over a 24-month period, suggesting that children readily adapted to the Diffusion Optics Technology^™. The CYPRESS trial is now continuing into its third year.

“Our team has been singularly focused on advancing medical science to not only correct children’s vision, but also to help slow the progression of myopia. Applying our Diffusion Optics Technology^™ to spectacle lenses makes myopia management straightforward to integrate within eye care practices and easy to become part of children’s everyday lives,”⁸ said Joe Rappon, OD, MS, FAAO, chief medical officer for SightGlass Vision.

Spectacle lenses incorporating SightGlass Vision^™ Diffusion Optics Technology™ already hold a CE Mark declaration to help slow the progression of myopia.

Earlier this year, CooperCompanies and EssilorLuxottica announced their intent to form a joint venture to accelerate the commercialization of technologies from SightGlass Vision.

Click HERE for the full press release.

October 6, 2021October 5, 2021

Changing Landscapes – Selling & Buying a Practice

The second event of the “Changing Landscapes: Opportunities & Options for Canadian ECPs will focus on Selling & Buying a Practice and will be held Monday November 1st (7:30 PM Eastern).

The Canadian market has experienced transformational change in the past year.

Mayor players have had substantial capital injection and new Canadian market entrants are making their play for market share, creating more opportunities and options for Canadian ECPs.

Join leaders and spokesperson from the world of independent optometry supported by B+L and major eye care groups/organizations including IRIS, FYidoctors, Vision Alliance Corporation, OSI/SOI, Eye Recommend and, new to Canada, Specsavers. ROI Corporation, Canada’s leading health practice brokerage will also share their experience

This event is a must-attend for any practitioner looking to exit their business, start a new practice or formulate a strategic partnership.

Speaker List Includes:

Jackie Joachim, Chief Operating Officer, ROI Corporation
Dr. Daryan Angle, VP Business Development, IRIS Group
Dr. Wes McCann, Central Optometry, ON, Eye Recommend
Dr. Michael Naugle, VP Optometric Partnerships, FYidoctors
Gord McFarlane, Managing Director of Corporate Development, FYidoctors
Dr. Skylar Feltis, YXE Vision Group, SK, OSI Group
Dr. Warren Toews, YXE Vision Group, SK, OSI Group
Dr. Trevor Miranda, Cowichan Eyecare, BC, Independent Practice
Dr. Robert Allaway, Chief Optometry Officer, Vision Alliance Corporation
Mike Protopsaltis, Partnerships Director, Specsavers

The event series will be moderated by Roxanne Arnal, OD and Certified Financial Planner (TM), bringing an informed and unique perspective to the events.

Event registration is now open. Click Here for Details.

PREMIER SPONSORS

PARTNER & FRIEND SPONSORS FOR THIS EVENT

Follow up Events:

The final event in the series will be held Monday November 8th 7:30 PM (Eastern).

Career Pathfinders| Making Informed Choices (November 8th)
Career options and opportunities for both young and experienced ODs have never been greater as new organizations offering unique business models enter the market and established entities respond to the changing environment.
Click Here for Detailed Information.

Registration for the first event Monday, October 25th, “Technology Drivers of Change” is open.
Click here for detailed information on this event.

Click here to register for any of the Changing Landscape Events